文献速递临床试验与 GCP基础与转化研究

儿童轻微结核短程治疗(SHINE):一项随机对照试验的研究方案

Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2018-04-19

SHINE 是一项多中心、开放标签、平行组、非劣效性、随机对照两臂试验,在非洲和印度招募 1200 名 16 岁以下非重症结核儿童,比较基于 WHO 修订儿童剂量的 4 个月与标准 6 个月方案。主要终点为随机化后 72 周无结核病生存和 3/4 级不良事件,并嵌套药代动力学、社会经济和社会科学研究。

要点

  • 儿童结核多为少菌性和非重症,治疗证据多从成人外推。
  • SHINE 比较 4 个月与 6 个月方案,使用 WHO 修订儿童剂量。
  • 主要终点为 72 周无结核病生存和 3/4 级不良事件。

核心结论

  • SHINE 将回答儿童药物敏感结核无论 HIV 状态如何,缩短治疗是否有效且安全。

研究设计与样本

  • 多中心、开放标签、平行组、非劣效性、随机对照两臂试验,比较 4 个月与标准 6 个月方案。
  • 计划招募 1200 名非洲和印度 16 岁以下非重症结核儿童,伴或不伴 HIV 感染。
  • 使用 WHO 修订的儿童抗结核药物剂量。

关键数值与推荐

  • 主要疗效终点为随机化后 72 周无结核病生存。
  • 主要安全性终点为 3 级或 4 级不良事件。

临床怎么用

  • 若结果阳性,可能简化并缩短治疗、提高依从性并节省费用。

局限性

  • 为研究方案,尚未报告结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) in children is frequently paucibacillary and non-severe forms of pulmonary TB are common. Evidence for tuberculosis treatment in children is largely extrapolated from adult studies. Trials in adults with smear-negative tuberculosis suggest that treatment can be effectively shortened from 6 to 4 months. New paediatric, fixed-dose combination anti-tuberculosis treatments have recently been introduced in many countries, making the implementation of World Health Organisation (WHO)-revised dosing recommendations feasible. The safety and efficacy of these higher drug doses has not been systematically assessed in large studies in children, and the pharmacokinetics across children representing the range of weights and ages should be confirmed. METHODS/DESIGN: SHINE is a multicentre, open-label, parallel-group, non-inferiority, randomised controlled, two-arm trial comparing a 4-month vs the standard 6-month regimen using revised WHO paediatric anti-tuberculosis drug doses. We aim to recruit 1200 African and Indian children aged below 16 years with non-severe TB, with or without HIV infection. The primary efficacy and safety endpoints are TB disease-free survival 72 weeks post randomisation and grade 3 or 4 adverse events. Nested pharmacokinetic studies will evaluate anti-tuberculosis drug concentrations, providing model-based predictions for optimal dosing, and measure antiretroviral exposures in order to describe the drug-drug interactions in a subset of HIV-infected children. Socioeconomic analyses will evaluate the cost-effectiveness of the intervention and social science studies will further explore the acceptability and palatability of these new paediatric drug formulations. DISCUSSION: Although recent trials of TB treatment-shortening in adults with sputum-positivity have not been successful, the question has never been addressed in children, who have mainly paucibacillary, non-severe smear-negative disease. SHINE should inform whether treatment-shortening of drug-susceptible TB in children, regardless of HIV status, is efficacious and safe. The trial will also fill existing gaps in knowledge on dosing and acceptability of new anti-tuberculosis formulations and commonly used HIV drugs in settings with a high burden of TB. A positive result from this trial could simplify and shorten treatment, improve adherence and be cost-saving for many children with TB. Recruitment to the SHINE trial begun in July 2016; results are expected in 2020. TRIAL REGISTRATION: International Standard Randomised Controlled Trials Number: ISRCTN63579542 , 14 October 2014. Pan African Clinical Trials Registry Number: PACTR201505001141379 , 14 May 2015. Clinical Trial Registry-India, registration number: CTRI/2017/07/009119, 27 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018. PMID: 29673395. doi:10.1186/s13063-018-2608-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。